Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
Top Cited Papers
Open Access
- 30 April 2014
- journal article
- practice guideline
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 99 (5), 811-820
- https://doi.org/10.3324/haematol.2013.099747
Abstract
Thalassemia major and sickle cell disease are the two most widely disseminated hereditary hemoglobinopathies in the world. The outlook for affected individuals has improved in recent years due to advances in medical management in the prevention and treatment of complications. However, hematopoietic stem cell transplantation is still the only available curative option. The use of hematopoietic stem cell transplantation has been increasing, and outcomes today have substantially improved compared with the past three decades. Current experience world-wide is that more than 90% of patients now survive hematopoietic stem cell transplantation and disease-free survival is around 80%. However, only a few controlled trials have been reported, and decisions on patient selection for hematopoietic stem cell transplantation and transplant management remain principally dependent on data from retrospective analyses and on the clinical experience of the transplant centers. This consensus document from the European Blood and Marrow Transplantation Inborn Error Working Party and the Paediatric Diseases Working Party aims to report new data and provide consensus-based recommendations on indications for hematopoietic stem cell transplantation and transplant management.Keywords
This publication has 100 references indexed in Scilit:
- Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell GraftsPLOS ONE, 2013
- Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell DiseaseTransplantation and Cellular Therapy, 2011
- Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)The Lancet, 2011
- HLA-matched sibling bone marrow transplantation for β-thalassemia majorBlood, 2011
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Improved survival of children and adolescents with sickle cell diseaseBlood, 2010
- Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell DiseaseThe New England Journal of Medicine, 2009
- Costs, quality of life, treatment satisfaction and compliance in patients with β-thalassemia major undergoing iron chelation therapy: the ITHACA studyCurrent Medical Research and Opinion, 2008
- Uncomplicated obesity is associated with abnormal aortic function assessed by cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 2008
- Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and PharmacokineticsTransplantation and Cellular Therapy, 2007